Zobrazeno 1 - 5
of 5
pro vyhledávání: '"S R, Goriacheva"'
Autor:
A L Melikian, I N Subortseva, S R Goriacheva, T I Kolosheĭnova, M V Vakhrusheva, A M Kovrigina, A B Sudarikov, V N Dvirnyk, T N Obukhova
Publikováno v:
Терапевтический архив, Vol 86, Iss 12, Pp 127-134 (2014)
The term mastocytosis (MC) encompasses a group of rare diseases characterized by the tumorous proliferation of clonal mast cells and the infiltration of one or several organs. The clinical picture of MC is extremely diverse from skin lesions that can
Externí odkaz:
https://doaj.org/article/e5078b08a1ec468b92897ee4ac3af83d
Autor:
A L Melikian, T I Kolosheĭnova, S R Goriacheva, I N Subortseva, M V Vakhrusheva, E N Kolosova, A B Sudarikov, A O Abdullaev, V N Dvirnyk, E Iu Varlamova, A M Kovrigina, A G Turkina
Publikováno v:
Терапевтический архив, Vol 86, Iss 7, Pp 37-44 (2014)
AIM. To determine the clinical features of multiple primary tumors (MPT) in patients with hemoblastoses, to develop treatment policy for synchronous and metachronous tumors, and to determine the impact of chemotherapy for one disease on the course an
Externí odkaz:
https://doaj.org/article/5f12c74511724a4182f454278733a615
Autor:
Vakhrusheva Mv, I N Subortseva, Alla M. Kovrigina, S R Goriacheva, T N Obukhova, V N Dvirnyk, Andrey Sudarikov, A L Melikian, T I Kolosheinova
Publikováno v:
Терапевтический архив, Vol 86, Iss 12, Pp 127-134 (2014)
Europe PubMed Central
Europe PubMed Central
The term mastocytosis (MC) encompasses a group of rare diseases characterized by the tumorous proliferation of clonal mast cells and the infiltration of one or several organs. The clinical picture of MC is extremely diverse from skin lesions that can
Autor:
O Iu, Vinogradova, A G, Turkina, A V, Vorontsova, E Iu, Chelysheva, G A, Gusarova, S V, Kuznetsov, S R, Goriacheva, M A, Sokolova, E M, Abakumov, O V, Stakhina, E V, Domracheva, A V, Misiurin, N D, Khoroshko
Publikováno v:
Terapevticheskii arkhiv. 81(7)
To analyse resistance to imatinib therapy, efficacy and safety of dasatinib.A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008.Lethal outcomes during d
Autor:
E A, Nikitin, Iu Iu, Lorie, A L, Melikian, R S, Samoĭlova, T I, Bulycheva, T N, Obukhova, I B, Kaplanskaia, V A, Doronin, L Iu, Kolosova, S R, Goriacheva
Publikováno v:
Terapevticheskii arkhiv. 75(7)
To assess factors of an unfavourable prognosis in a group of intermediate risk of B-cell chronic lymphoid leukemia (BCCLL).206 BCCLL patients (mean age 55.5 years, male/female = 1.66) entered the study conducted by Hematological Research Center in 19